Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic
CAMBRIDGE, Mass. -- May 16, 2013
Atlas Venture is pleased to announce that it has entered into Corporate
Strategic Partnership (CSP) agreements with both Amgen, through its venture
capital fund, Amgen Ventures, and Novartis. The CSP agreements are in
conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis
are new limited partners.
The intent of these relationships is to provide Amgen and Novartis with
strategic proximity to Atlas Venture’s startup formation activities around
innovative, potentially high impact medicines, and catalyze future
collaborations around translational research across Atlas Venture’s early
stage portfolio. Amgen and Novartis bring their deep knowledge in
pharmaceutical R&D with Atlas Venture’s focus on creating and building new
biomedical startups with experienced entrepreneurs.
These CSP relationships are further momentum around the increasingly
collaborative early stage biotech ecosystem, bringing venture and pharma
interests together. Under the agreements, Atlas Venture intends to explore a
range of new opportunities with Amgen and Novartis including co-creation of
life sciences startups, formation of asset-centric development projects, and
helping translate discoveries from ongoing academic collaborations, among
"Amgen is very excited to partner with Atlas Venture, one of a small number of
venture capital groups that truly focuses on creating value by translating
groundbreaking science into new companies,” said Sean E. Harper, M.D.,
executive vice president of Research and Development at Amgen.
“This partnership will enable us to help some of the best and the brightest
academic scientists and biotech entrepreneurs get their ideas off the ground,”
said Mark C. Fishman, President of Novartis Institutes for BioMedical Research
(NIBR). “We look forward to working with the Atlas team to build young
start-ups that will hopefully one day lead to the development of new medicines
for patients in need.”
The agreements do not constitute exclusivity or any commitment of Amgen or
Novartis to pursue opportunities. Atlas Venture maintains full authority over
funding strategy and investment decisions. This “open market” principle is an
important element of these CSP relationships, which are designed to facilitate
the partners exploring opportunities of mutual strategic interest. Atlas IX is
expected to create and/or fund more than fifteen new biotech companies, and we
anticipate these new CSP relationships will be integral part of facilitating
their launch and progression.
About Atlas Venture
Atlas Venture is a leading early-stage venture capital firm that invests in
technology and life sciences companies. Since inception in 1980, we have
helped build over 350 companies. Atlas Venture is currently investing from its
ninth fund. For more information, please visit www.atlasventure.com.
Matt Burke, +1 603-315-0618
Press spacebar to pause and continue. Press esc to stop.